We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-10%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.64B
AUM Growth
-$98.2M
Cap. Flow
+$187M
Cap. Flow %
11.36%
Top 10 Hldgs %
46.02%
Holding
79
New
7
Increased
13
Reduced
45
Closed
4

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.9M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$23.3M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$18.4M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$18.2M
5
QURE icon
uniQure
QURE
+$17.3M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$20.8M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$15.6M
3
ALLK
Allakos
ALLK
+$13.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$11.3M
5
ANAB icon
AnaptysBio
ANAB
+$5.18M

Sector Composition

Rank Sector Weight
1 Healthcare 82.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
76
CALL
uniQure
QURE
$3.07B
– –
-100,000
Closed -$7.82M
VRTX icon
77
Vertex Pharmaceuticals
VRTX
$123B
– –
-85,000
Closed -$15.6M
CLRBW
78
DELISTED
Cellectar Biosciences, Inc.
CLRBW
– –
-52,999
Closed -$3K
ARRY
79
DELISTED
Array Biopharma Inc
ARRY
– –
-450,000
Closed -$20.8M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2019 Portfolio in Review

As of Q3 2019, Cormorant Asset Management held 79 positions worth $1.64B, down 5.6% from $1.74B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $187M of net new capital in Q3 2019, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Allakos, an estimated $13.6M trimmed.

  • Cormorant Asset Management's largest Q3 2019 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.
  • Cormorant Asset Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $46.9M increase.
  • Cormorant Asset Management's biggest Q3 2019 reduction was Allakos, cutting an estimated $13.6M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $20.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.64B portfolio in Q3 2019.
  • Cormorant Asset Management opened 7 new positions and closed 4 in Q3 2019.
  • Cormorant Asset Management's portfolio value fell 5.6% quarter-over-quarter to $1.64B.

Based on Cormorant Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.